Mechanism of Action
GLP-2 Receptor Activation
Teduglutide binds the GLP-2 receptor expressed on intestinal enteroendocrine cells and subepithelial myofibroblasts. Receptor activation triggers downstream signaling through adenylate cyclase and PKA, promoting enterocyte proliferation, reducing apoptosis, and increasing crypt depth and villus height. These trophic effects enhance the absorptive surface area of the remaining intestine.
Intestinal Blood Flow and Barrier Function
Beyond epithelial growth, teduglutide increases intestinal blood flow and strengthens tight junction integrity. Improved barrier function reduces bacterial translocation and intestinal permeability. Enhanced mesenteric blood flow improves nutrient delivery and oxygen supply to intestinal epithelium, supporting adaptation.
Research Summary
Short Bowel Syndrome
FDA ApprovedPhase 3 trials (STEPS) demonstrated that teduglutide 0.05 mg/kg/day significantly reduced parenteral nutrition requirements versus placebo over 24 weeks in SBS patients. Approximately 63% of teduglutide patients achieved a 20% reduction in parenteral nutrition versus 30% on placebo. Several patients achieved complete parenteral nutrition independence.
Pediatric SBS
FDA ApprovedTeduglutide received approval for pediatric SBS patients aged 1 year and older based on the STEPS-2 trial. Pediatric patients showed similar reductions in parenteral nutrition requirements. Structural adaptations including increased villus height and crypt depth were confirmed on biopsy.
Calculate your Teduglutide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Adult SBS treatment | 0.05 mg/kg | Once daily | Subcutaneous injection |
| Pediatric SBS (1+ year) | 0.05 mg/kg | Once daily | Subcutaneous injection |
Requires colonoscopy before initiation and annually. Monitor for polyp development.
Interactions
Safety Profile
Most common adverse effects are abdominal pain, nausea, injection site reactions, and fluid retention. The trophic effect raises concern for accelerated neoplastic growth; colonoscopy is required before initiation and annually. Teduglutide is contraindicated in patients with active gastrointestinal malignancy. Fluid retention and cardiac decompensation have been reported in heart failure patients.
References
- [1]Jeppesen PB et al. (2012). Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology, 143(6), 1473-1481.
- [2]Schwartz LK et al. (2016). Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clinical and Translational Gastroenterology, 7(2), e142.